Scala Biodesign exits stealth with Seed funding to engineer proteins of the future

TEL AVIV — September 11, 2023 — Scala Biodesign exited stealth today, revealing $5.5M of funding for their solution to dramatically improve and speed up the development of proteins into biotech products. The seed round was led by TLV Partners.

Custom antibody therapies, vaccines, food products, and clean production of chemicals: proteins are revolutionizing multiple industries. But developing and mass-producing custom proteins is a long, expensive, and uncertain process because natural proteins are almost never suitable for industry — they are often unstable, costly to manufacture, and insufficiently active.

Protein engineering can modify a protein into an industrial-grade product, but current engineering methods rely on iterative trial-and-error testing of thousands and often millions of versions in the lab. This process can take years, cost millions, and often fails.

Scala makes it possible to engineer and improve proteins immediately and in one shot. Fusing physics-based modeling, AI, and biological data analysis, Scala enables companies to develop new medicines, green production processes, and foods radically faster and cheaper, allowing the creation of entirely new applications of biotechnology that weren’t possible using traditional methods.

Scala was founded by Dr. Ravit Netzer (CEO) and Dr. Adi Goldenzweig (CTO), who researched the challenges…